Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
36.70
+3.47 (10.44%)
At close: Apr 24, 2025, 4:00 PM
36.17
-0.53 (-1.44%)
Pre-market: Apr 25, 2025, 5:01 AM EDT
Summit Therapeutics Employees
Summit Therapeutics had 159 employees as of December 31, 2024. The number of employees increased by 54 or 51.43% compared to the previous year.
Employees
159
Change (1Y)
54
Growth (1Y)
51.43%
Revenue / Employee
n/a
Profits / Employee
-$1,391,918
Market Cap
27.07B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 159 | 54 | 51.43% |
Dec 31, 2023 | 105 | 28 | 36.36% |
Dec 31, 2022 | 77 | -33 | -30.00% |
Dec 31, 2021 | 110 | 29 | 35.80% |
Dec 31, 2020 | 81 | 11 | 15.71% |
Dec 31, 2019 | 70 | 9 | 14.75% |
Dec 31, 2018 | 61 | -15 | -19.74% |
Dec 31, 2017 | 76 | 36 | 90.00% |
Dec 31, 2016 | 40 | 3 | 8.11% |
Dec 31, 2015 | 37 | 14 | 60.87% |
Dec 31, 2014 | 23 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
SMMT News
- 13 hours ago - Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025 - Business Wire
- 1 day ago - Why Is Summit Therapeutics Stock Soaring On Wednesday? - Benzinga
- 1 day ago - Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China - Business Wire
- 10 days ago - Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition - Seeking Alpha
- 20 days ago - Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics - Benzinga
- 5 weeks ago - Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer - Business Wire
- 2 months ago - Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs - PRNewsWire